Britain and America have forged a major commercial pact that will guarantee no tariffs on UK pharmaceutical shipments entering the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase funding on medicines through the National Health Service (NHS). This pledge ensures that tariffs on these key goods will remain at nothing for a period of 36 months.
This deal comes after previous threats to significantly raise import taxes on patented pharmaceutical imports, with figures floated up to 100%.
"This deal between the United Kingdom bolsters the global environment for new treatments and introduces long-overdue equity to U.S.–U.K. pharmaceutical trade," a release said.
Commercial Importance
Pharmaceuticals represent one of the UK's most significant exports to the America, which is by far the biggest buyer for leading UK drugmakers.
Export figures show that in the 12 months prior to September, the UK sold drugs totaling £11.1bn to the US. This amount represented nearly one-fifth of total UK exports in that period.
"This agreement protects employment, increases capital expenditure and sets the stage for the UK to become a worldwide center for medical research," a government official commented.
Detailed UK Commitments
The pact includes several notable commitments from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a target to double total public funding on medicines from 0.3% of the national economy to 0.6% over the next decade.
- Refund Ceiling: The sum manufacturers must return to the NHS to control costs will be limited at fifteen percent. Previously, repayments were more than 20%.
Broader Context
The deal follows a protracted tension between the drug companies and the ministers over spending levels and regulatory access.
This friction were exacerbated by arguments that American patients were paying significantly more for the identical medicines than consumers in the Britain and the EU.
Recently, several major drug company projects in the UK have been halted or cancelled, while major funding commitments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had declined as a share of its overall budget over the past decade.
